Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 22, 2016 12:21:02 GMT -5
If $15.00 a month on a co pay is too much for your health, ouch! There isn't much profit margin in $15 a month. Lol $15 is copayment that the patients pay to pharmacy.. Insurance pays the rest . Have you had ever filled an RX and looked into your prescription plan? At $15 cost, even the target of 6.5 million diabetics wouldn't even pay for a Mannkind. They better close the shop and stop the agony |
|
|
|
Post by babaoriley on Aug 22, 2016 12:21:30 GMT -5
If $15.00 a month on a co pay is too much for your health, ouch! There isn't much profit margin in $15 a month. Just like street drugs - first you get them hooked, then you make your money, plus it's the insurers that are picking up the lion's share, not the patient. |
|
|
|
Post by mnholdem on Aug 22, 2016 12:30:40 GMT -5
You beat me to it, baba. To clarify, MannKind will make a profit off the wholesale price that is billed to the 3rd party payers. Another reason why you won't see MannKind significantly lower the retail price of Afrezza (see MannKind website FAQ, Aug 2016) is because they need wriggle room in negotiating rebates with the BPMs / payers.
|
|
|
|
Post by flatrock on Aug 22, 2016 13:03:01 GMT -5
There isn't much profit margin in $15 a month. Lol $15 is copayment that the patients pay to pharmacy.. Insurance pays the rest . Have you had ever filled an RX and looked into your prescription plan? At $15 cost, even the target of 6.5 million diabetics wouldn't even pay for a Mannkind. They better close the shop and stop the agony But if the insurance company doesn't cover it, then MNKD collects nothing? |
|
|
|
Post by mnholdem on Aug 22, 2016 14:22:46 GMT -5
The copay program has a maximum benefit. If a patient's insurance pays nothing, then the patient will need to pay more than $15. Simple as that.
|
|
|
|
Post by tingtongtung on Aug 22, 2016 14:56:34 GMT -5
What exactly is the payment coming from SNY? It says just one payment later this year, and then it also says for the next 2 years. Any idea what's negotiated?
Thanks!
|
|
|
|
Post by agedhippie on Aug 22, 2016 16:02:47 GMT -5
I didn't know this... Under the terms negotiated with Sanofi, another Payment from them is anticipated late this year, and payments will continue to be made periodically for at least the next couple of years. So $9.2mm received in Q2-16, maybe another $9-$10mm received in Q4-16? Wonder if they negotiated semi-annual payments. So a possible RLS milestone and another Sanofi put in Q4-16 could give them another quarter worth of cash next year. |
|
|
|
Post by agedhippie on Aug 22, 2016 16:06:17 GMT -5
I didn't know this... Under the terms negotiated with Sanofi, another Payment from them is anticipated late this year, and payments will continue to be made periodically for at least the next couple of years. So $9.2mm received in Q2-16, maybe another $9-$10mm received in Q4-16? Wonder if they negotiated semi-annual payments. So a possible RLS milestone and another Sanofi put in Q4-16 could give them another quarter worth of cash next year. The payments are from Mannkind selling on part of the the Amphastar insulin delivery. Mannkind pays around $13 million and then resells up to 65% ($9 million) to Sanofi. Expect a put every time Mannkind has to take delivery from Amphastar. |
|
|
|
Post by tingtongtung on Aug 22, 2016 16:13:51 GMT -5
So $9.2mm received in Q2-16, maybe another $9-$10mm received in Q4-16? Wonder if they negotiated semi-annual payments. So a possible RLS milestone and another Sanofi put in Q4-16 could give them another quarter worth of cash next year. The payments are from Mannkind selling on part of the the Amphastar insulin delivery. Mannkind pays around $13 million and then resells up to 65% ($9 million) to Sanofi. Expect a put every time Mannkind has to take delivery from Amphastar. Thank you! I missed it completely.. At the risk of asking another "already answered question".. MNKD sells 65% of insulin bought form AMPH. Do they make any profit off of it? AFAIK, MNKD has to buy at the most $50mil of insulin from AMPH - is that right? Thanks! |
|
|
|
Post by madog365 on Aug 22, 2016 16:18:55 GMT -5
So it looks liked Mannkind invoked the full amount for the insulin put (50M) which can be used only on insulin deliveries from amphastar. Does this money pay for all of the insulin that is used to make Afrezza? If they chose to, can Mannkind settle with Sanofi for cash instead at a later date?
The other thing i don't understand is why is there still a significant # of employees at Sanofi who are dedicated to only Afrezza? I am seeing at least 5 employees or so on Linked In who list Afrezza marketing as their primary position. How much is Sanofi still involved if there are people going to work each day focused on Afrezza.
|
|
|
|
Post by nylefty on Aug 22, 2016 16:30:53 GMT -5
The other thing i don't understand is why is there still a significant # of employees at Sanofi who are dedicated to only Afrezza? I am seeing at least 5 employees or so on Linked In who list Afrezza marketing as their primary position. How much is Sanofi still involved if there are people going to work each day focused on Afrezza. Obvious answer: Five Sanofi employees haven't gotten around to changing their LinkedIn profiles. Do a search for "Sanofi" on LinkedIn and you'll find 52,912 entries. I haven't changed my profile there either since I no longer have any reason to use LinkedIn. |
|
|
|
Post by agedhippie on Aug 22, 2016 18:41:45 GMT -5
The payments are from Mannkind selling on part of the the Amphastar insulin delivery. Mannkind pays around $13 million and then resells up to 65% ($9 million) to Sanofi. Expect a put every time Mannkind has to take delivery from Amphastar. Thank you! I missed it completely.. At the risk of asking another "already answered question".. MNKD sells 65% of insulin bought form AMPH. Do they make any profit off of it? AFAIK, MNKD has to buy at the most $50mil of insulin from AMPH - is that right? Thanks! It's difficult to tell the resale price since it's starred out in the public copy of the agreement but I would think it's extremely unlikely to be marked up. The clause is there to limit Mannkind's exposure in the event of a termination by Sanofi so Mannkind does not bear the cost of the Amphastar contract alone, but only their (35%) share up to that $50 million cap. The contract is very clear about saying that $50 million is the limit of the funding. Within the life of the contract Mannkind may well need more than 35% of the insulin and the put allows them to keep what they need in that case and only pass on the balance (eg. a 50:50 split). |
|
|
|
Post by agedhippie on Aug 22, 2016 18:47:13 GMT -5
So it looks liked Mannkind invoked the full amount for the insulin put (50M) which can be used only on insulin deliveries from amphastar. Does this money pay for all of the insulin that is used to make Afrezza? If they chose to, can Mannkind settle with Sanofi for cash instead at a later date? The other thing i don't understand is why is there still a significant # of employees at Sanofi who are dedicated to only Afrezza? I am seeing at least 5 employees or so on Linked In who list Afrezza marketing as their primary position. How much is Sanofi still involved if there are people going to work each day focused on Afrezza. Mannkind did not invoke the whole $50 million, nor can they at this point since nowhere near that amount of insulin has been delivered. The money does not pay for insulin used to make Afrezza since it is delivered to Sanofi. There is a time limit within which Mannkind has to exercise their put for any given delivery. |
|
|
|
Post by od on Aug 22, 2016 18:51:54 GMT -5
They think pricing is not an impediment? With some competing insulins costing next to nothing due to insurance coverage, how could pricing not be an impediment? Uh that isnt a pricing issue if they cost nearly the same whole sale that is an insurance coverage issue. Just like obamacare(health insurance) isnt health care. Apples are not oranges but people keep trying to say they are...... Anderson, help me understand "Just like obamacare (health insurance) isn't health care". Thanks. |
|
|
|
Post by flatrock on Aug 22, 2016 19:08:29 GMT -5
The copay program has a maximum benefit. If a patient's insurance pays nothing, then the patient will need to pay more than $15. Simple as that. That's what was I was aiming at in my original answer to the other post -- $15 doesn't offer much profit margin. |
|
